Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    No additions or deletions affecting core page content were detected; the study overview and eligibility details appear unchanged.
    Difference
    0.2%
    Check dated 2025-10-30T15:23:01.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    39 days ago
    Change Detected
    Summary
    Major update to core content with a funding-status notice and a version upgrade from v3.0.2 to v3.2.0.
    Difference
    3%
    Check dated 2025-10-02T01:17:43.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Version bumped from v3.0.2 to v3.1.0; no other substantive content changes detected.
    Difference
    0.1%
    Check dated 2025-09-30T14:33:03.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The page has been updated to revision v3.0.2, replacing v3.0.1, and the 'Back to Top' link was removed.
    Difference
    0.2%
    Check dated 2025-09-16T05:41:12.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-09T01:20:41.000Z thumbnail image
  8. Check
    69 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility names and locations, as well as drug information related to Pemetrexed and other compounds. Notably, several locations in South Korea, Turkey, and Vietnam have been added, while previous entries for certain locations and related topics have been removed.
    Difference
    32%
    Check dated 2025-09-01T21:09:19.000Z thumbnail image

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.